formula i are useful to treat prevent or ameliorate in mammals and especially in humans 2 pulmonary disorders including diseases such as asthma chronic bronchitis and related airway diseases 3 allergies and allergic reactions such as allergic rhinitis contact dermatitis allergic conjunctivitis and the like 6 disorders of the immune system such as lupus aids etc 8 vomiting and nausea and vertigo especially in the case of chemotherapy patients the magnitude of therapeutic dose of a compound of formula i will of course vary with the nature of the severity of the condition to be treated and with the particular compound of formula i and its route of administration and vary upon the clinician 39 s judgment it will also vary according to the age weight and response of the individual patient an effective dosage amount of the active component can thus be determined by the clinician after a consideration of all the criteria and using is best judgment on the patient 39 s behalf an ophthalmic preparation for ocular administration comprising 0 001 1 by weight solutions or suspensions of the compounds of formula i in an acceptable ophthalmic formulation may be used any suitable route of administration may be employed for providing a mammal especially a human with an effective dosage of a compound of the present invention for example oral parenteral and topical may be employed dosage forms include tablets troches dispersions suspensions solutions capsules creams ointments aerosols and the like the pharmaceutical compositions of the present invention comprise a compound of formula i as an active ingredient or a pharmaceutically acceptable salt thereof and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients the term 34 pharmaceutically acceptable salts 34 refers to salts prepared from.